Прогностическая ценность чрескожного коронарного вмешательства при сердечной недостаточности с промежуточной фракцией выброса

Литература:
1. Мареев В.Ю., Фомин И. В., Агеев Ф.Т. и др. Клинические рекомендации ОССН — РКО — РНМОТ: Сердечная недостаточность: хроническая (ХСН) и острая декомпенси-рованная (ОДСН): диагностика, профилактика и лечение. Кардиология 2018; 58 (6S): 8-158). DOI: 10.18087/cardio. 2475.
2. Карпов Ю.А., Кухарчук В. В., Лякишев А. А. и др. Диагностика и лечение хронической ишемической болезни сердца (практические рекомендации). Кардиологический вестник 2015; (3): 3-33). ISSN: 2077-6764. 3. Fox KF, Cowie MR, Wood DA, et al. Coronary artery disease as the cause of incident heart failure in the population. Eur Heart J 2001; 22 (3): 228-36. DOI: 10.1053/euhj. 2000.2289.
4. Roger VL. Epidemiology of heart failure. Circulation research 2013; 113 (6): 646-59. DOI: 10.1161/CIRCRESAHA. 113.300268.
5. Cheng RK, Cox M, Neely ML, et al. Outcomes in patients with heart failure with preserved, borderline, and reduced ejection fraction in the Medicare population. Am Heart J 2014; 168: 721-30. DOI: 10.1016/j. ahj. 2014.07.008.
6. Kapoor JR, Kapoor R, Ju C, et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC: Heart Failure 2016; 4: 464-72. DOI:10.1016/j. jchf. 2016.02.017.
7. Tsuji K, Sakata Y, Nochioka K, et al. Characterization of heart failure patients with midrange left ventricular ejection fraction — a report from the CHART-2 Study. Eur J Heart Fail 2017; 19 (10): 1258-69. DOI: 10.1002/ejhf. 807.
8. Sousa-Uva M, Neumann FJ, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur J Cardio-Thorac Surg 2018; 55 (1): 4-90. DOI: 10.1093/ejcts/ezy289.
9. Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation 1995; 92 (12): 3436-44. DOI: 10.1161/01. CIR. 92.12.3436.
10. Bax JJ, Visser FC, Poldermans D, et al. Relationship between preoperative viability and postoperative improvement in LVEF and heart failure symptoms. J Nucl Med 2001; 42 (1): 79-86. PMID: 11197985.
11. Peovska I, Maksimovic J, VavlukisM, et al. Functional outcome and quality of life after coronary artery bypass surgery in patients with severe heart failure and hibernated myocardium. Nuclear medicine communications 2008; 29 (3): 215-21. DOI: 10.1097/MNM. 0b013e3282f3add9.
12. Pagano D, Townend JN, Littler WA, et al. Coronary artery bypass surgery as treatment for ischemic heart failure: the predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome. J Thorac Cardiovasc Surg 1998; 115 (4): 791-9. DOI: 10.1016/S0022-5223(98) 70357-5.
13. Abraham A, Nichol G, Williams KA, et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR-2 trial. J Nucl Med 2010; 51 (4): 567-74. DOI: 10.2967/jnumed. 109.065938.
14. SchinkelAFL, Bax JJ, Poldermans D, et al. Hibernating myocardium: diagnosis and patient outcomes. Current problems in cardiology 2007; 32 (7): 375-410. DOI: 10.1016/j. cpcardiol. 2007.04.001.
15. Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circulation: Cardiovascular Imaging 2013; 6(3): 363-72. DOI: 10.1161/CIRCIMAGING. 112.000138.
16. Beanlands RSB, Nichol G, Huszti E, et al. F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction and suspected coronary disease: a randomized, controlled trial (PARR-2). J Am Coll Cardiol 2007; 50 (20): 2002-12. DOI: 10.1016/j.jacc. 2007.09.006.
17. D'Egidio G, Nichol G, Williams KA, et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. J Am Coll Cardiol Cardiovasc Imaging 2009; 2 (9): 1060-8. DOI: 10.1016/j. jcmg. 2009.02.017.
18. Beanlands RSB, Ruddy TD, Iwanochko RM, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol 2002; 40 (10): 1735-43. DOI: 10.1016/S0735-1097(02) 02489-0.
19. McArdle B, ShuklaT, Nichol G, etal. Long-term follow-up of outcomes with F-18-fluorodeoxyglucose positron emission tomography imaging-assisted management of patients with severe left ventricular dysfunction secondary to coronary disease. Circulation: Cardiovascular Imaging 2016; 9 (9): e004331. DOI: 10.1161/CIRCIMAGING. 115.004331.
20. Gerber BL, Rousseau MF, Ahn SA, et al. Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy. J Am Coll Cardiol 2012; 59 (9): 825-35. DOI: 10.1016/j. jacc. 2011.09.073.
21. Pagano D, Bonser RS, Townend JN, et al. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure. Heart 1998; 79 (3): 281-8. DOI: 10.1136/hrt. 79.3.281.
22. Di Carli MF, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994; 73 (8): 527-33. DOI: 10.1016/0002-9149(94) 90327-1.
23. Allman КС, Shaw LJ, Hachamovitch R, et al. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol 2002; 39(7): 1151-8. DOI: 10.1016/S0735-1097 (02) 01726-6.
24. Bonow RO, Maurer G, Lee KL, et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011; 364 (17): 1617-25. DOI: 10.1056/NEJMoa1100358.
25. PanzaJA, Holly ТА,Asch FM, etal. Inducible myocardial ischemia and outcomes in patients with coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol2013; 61 (18): 1860-70. DOI: 10.1016/j. jacc. 2013.02.014.
26. Остроумов E.H., Бар-калая H.A., Хорикова Е.Н. и др. Результаты STICH: реваску-ляризируем рубцы? Медицинская визуализация 2011; (6): 103-8). ISSN: 1607-0763.
27. Page BJ, Banas MD, Suzuki G, et al. Revascularization of chronic hibernating myocardium stimulates myocyte proliferation and partially reverses chronic adaptations to ischemia. J Am Coll Cardiol 2015; 65 (7): 684-97. DOI: 10.1016/j. jacc. 2014.11.040.
28. Mock MB, Ringqvist I, Fisher LD, et al. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1982; 66 (3): 562-8. PMID: 6980062.
29. Wallace TW, Berger JS, Wang A, et al. Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. Am J Cardiol 2009; 103 (3): 355-60. DOI: 10.1016/j. amjcard. 2008.09.088.
30. Alidoosti M, Salarifar M, Zeinali АМН, et al. Short-and long-term outcomes of percutaneous coronary intervention in patients withlow, intermediate and high ejection fraction. Cardiovascular journal of Africa 2008; 19 (1): 17-21. PMID: 18320081.
31. NozariY, Oskouei NJ, KhazaeipourZ. Effect of elective percutaneous coronary intervention on left ventricular function in patients with coronary artery disease. Acta Medica Iranica 2012; 50 (1): 26-30. PMID: 22267375.
32. Trevisan L, Cautela J, Resseguier N, et al. Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: A systematic angiography approach. Arch Cardiovasc Dis2017; 111 (2): 109-18. DOI: 10.1016/j. acvd. 2017.05.006.